June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

CGM Boosts Wound Healing, Lowers A1c: Study

Short-term CGM use improved A1c, wound healing, and reduced ED visits in diabetic foot patients, per data from ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

Ecnoglutide Shows Strong Weight Loss in Trial

A once-weekly GLP-1 receptor agonist, ecnoglutide, led to significant and sustained weight loss in a large study of adults with overweight or obesity, with favorable safety outcomes reported at the ADA’s 85th Scientific Sessions.

Conexiant

June 27, 2025

Once-Monthly Drug Cuts Weight by 16%: Study

A once-monthly injectable GLP-1/GIP modulator demonstrated substantial weight loss in adults with obesity, with or without type 2 diabetes.

Conexiant

June 25, 2025

Combo Obesity Therapy Preserves Muscle, Reduces Fat

A new combination therapy of semaglutide and bimagrumab helped patients lose more fat while preserving muscle mass, while a novel biosensor may help track muscle loss during obesity treatment.

Conexiant

June 23, 2025

Gut Microbiome May Hold Key to Avoiding Chemotherapy-Related Cardiotoxicity in Patients With Breast Cancer

A healthy gut microbiome prior to chemotherapy could help protect against cardiotoxicity as a result of breast cancer therapy, according to findings presented at the European Society of Cardiology (ES...

The ASCO Post

June 20, 2025

Gut Bacteria Predict Chemotherapy-Related Heart Damage

Specific gut bacteria correlate with biomarkers indicating increased risk of cardiotoxicity in breast cancer patients before chemotherapy treatment.

Conexiant

June 18, 2025

Weight Loss Showdown: Pills or Scalpel?

A large analysis presented at the ASMBS Annual Meeting found bariatric surgery led to greater long-term weight loss than GLP-1 medications semaglutide and tirzepatide over three years.

Conexiant

June 17, 2025

Is Stroke Risk Lower with Semaglutide?

Semaglutide lowered stroke risk compared to empagliflozin in adults with type 2 diabetes, though overall mortality and heart attack rates were similar between the two drugs.

Conexiant